Related to this, it has been demonstrated recently that a synthetic analogue of PACAP with preference to PAC1R and relatively low affinity towards the VPAC receptors is as efficient as PACAP protecting against MPTP toxicity in a PD animal model (Lamine et al., 2016). Here, ADCYAP1 is linked to Parkinson disease.